Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition

Cell Cycle

Volumn 10, Issue 20, 2011, Pages 3598-3607

  Höglund, Andreas ^a   Strömvall, Kerstin ^a   Li, Yongmei ^a,c   Forshell, Linus Plym ^a   Nilsson, Jonas A ^a,b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

ABT 888; AZD 7762; Chk1; Chk2; DNA damage; Lymphoma; Myc; PARP

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL DEATH; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; CHECKPOINT KINASE 2 DEFICIENCY; CHEMOTHERAPY; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; ENZYME DEFICIENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INTESTINE; LYMPHOMA CELL; MALE; MOUSE; NONHUMAN; POLYPLOIDY; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

EID: 80055108191     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.20.17887     Document Type: Article

References (62)

1. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006; 16:253-64; PMID:16904903; DOI:10.1016/j.semcancer.2006.07.014.
2. Hydbring P, Larsson LG. Cdk2: a key regulator of the senescence control function of Myc. Aging (Albany NY) 2010; 2:244-50; PMID:20445224.
3. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003; 22:9007-21; PMID:14663479; DOI:10.1038/sj.onc.1207261.
4. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13; PMID:15829965; DOI:10.1038/nature03485.
5. Seviour EG, Lin SY. The DNA damage response: Balancing the scale between cancer and ageing. Aging (Albany NY) 2010; 2:900-7; PMID:21191148.
6. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-68; PMID:12612651; DOI:10.1038/nrc1011.
7. Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999; 18:4047-54; PMID:10435585; DOI:10.1038/sj.onc.1202925.
8. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000; 14:1448-59; PMID:10859164.
9. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000; 97:10389-94; PMID:10973490; DOI:10.1073/pnas.190030497.
10. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421-9; PMID:12781359; DOI:10.1016/S1535-6108(03) 00110-7.
11. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000; 287:1824-7; PMID:10710310; DOI:10.1126/science.287.5459.1824.
12. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14:289-300; PMID:10673501.
13. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31; PMID:9039259; DOI:10.1016/S0092-8674(00)81871-1.
14. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 2000; 14:1439-47; PMID:10859163.
15. Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002; 21:5195-205; PMID:12356735; DOI:10.1093/emboj/ cdf506.
16. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286:2528-31; PMID:10617473; DOI:10.1126/science.286.5449.2528.
17. Cipollini G, Tommasi S, Paradiso A, Aretini P, Bonatti F, Brunetti I, et al. Genetic alterations in hereditary breast cancer. Ann Oncol 2004; 15:7-13; PMID:15280181; DOI:10.1093/annonc/mdh651.
18. Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber DA. Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res 2006; 66:1923-8; PMID:16488990; DOI:10.1158/0008-5472.CAN-05- 1237.
19. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, et al. Non-transcriptional control of DNA replication by c-Myc. Nature 2007; 448:445-51; PMID:17597761; DOI:10.1038/nature05953.
20. Höglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009; 113:4281-8; PMID:19179467; DOI:10.1182/blood-2008-10-183475.
21. Maclean KH, Keller UB, Rodriguez-Galindo C, Nilsson JA, Cleveland JL. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol 2003; 23:7256-70; PMID:14517295; DOI:10.1128/MCB.23.20.7256-70.2003.
22. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligandbinding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995; 23:1686-90; PMID:7784172; DOI:10.1093/nar/23.10.1686.
23. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90:7804-8; PMID:8356088; DOI:10.1073/pnas.90.16.7804.
24. Ahn JY, Li X, Davis HL, Canman CE. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J Biol Chem 2002; 277:19389-95; PMID:11901158; DOI:10.1074/jbc.M200822200.
25. Anderson VE, Walton MI, Eve PD, Boxall KJ, Antoni L, Caldwell JJ, et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res 2011; 71:463-72; PMID:21239475; DOI:10.1158/0008-5472.CAN-10-1252.
26. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509-12; PMID:9727977; DOI:10.1126/science.281.5382.1509.
27. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992; 256:668-70; PMID:1350108; DOI:10.1126/science. 1350108.
28. Stolz A, Ertych N, Kienitz A, Vogel C, Schneider V, Fritz B, et al. The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol 2010; 12:492-9; PMID:20364141; DOI:10.1038/ncb2051.
29. Hsu LC, White RL. BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci USA 1998; 95:12983-8; PMID:9789027; DOI:10.1073/pnas.95.22. 12983.
30. Joukov V, Groen AC, Prokhorova T, Gerson R, White E, Rodriguez A, et al. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 2006; 127:539-52; PMID:17081976; DOI:10.1016/j.cell.2006.08.053.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; DOI:10.1016/j.cell.2011.02.013.
32. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001; 410:842-7; PMID:11298456; DOI:10.1038/35071124.
33. Brown AL, Lee CH, Schwarz JK, Mitiku N, Piwnica- Worms H, Chung JH. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. Proc Natl Acad Sci USA 1999; 96:3745-50; PMID:10097108; DOI:10.1073/pnas.96.7.3745.
34. Ashwell S, Zabludoff S. DNA damage detection and repair pathways - recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008; 14:4032-7; PMID:18593978; DOI:10.1158/1078-0432.CCR-07-5138.
35. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-66; PMID:18790776; DOI:10.1158/1535-7163.MCT-08-0492.
36. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7:517-28; PMID:16829982; DOI:10.1038/nrm1963.
37. Altmeyer M, Hottiger MO. Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and inflammation in aging. Aging (Albany NY) 2009; 1:458-69; PMID:20157531.
38. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 2005; 434:913-7; PMID:15829966; DOI:10.1038/nature03443.
39. Williams RS, Williams JS, Tainer JA. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling and the chromatin template. Biochem Cell Biol 2007; 85:509-20; PMID:17713585; DOI:10.1139/O07-069.
40. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010; 11:138-48; PMID:20029420; DOI:10.1038/nrm2831.
41. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; DOI:10.1038/nature03445.
42. Sørensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, et al. The cell cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7:195-201; PMID:15665856; DOI:10.1038/ncb1212.
43. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004; 24:708-18; PMID:14701743; DOI:10.1128/MCB.24.2.708-18.2004.
44. Zhuang J, Zhang J, Willers H, Wang H, Chung JH, van Gent DC, et al. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res 2006; 66:1401-8; PMID:16452195; DOI:10.1158/0008-5472.CAN-05-3278.
45. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13:2728-37; PMID:17473206; DOI:10.1158/1078-0432.CCR-06-3039.
46. Chou TC. Theoretical basis, experimental design and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81; PMID:16968952; DOI:10.1124/pr.58.3.10.
47. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009; 8:45-54; PMID:19139112; DOI:10.1158/1535-7163.MCT-08-0662.
48. Forshell TP, Rimpi S, Nilsson JA. Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. Cancer Prev Res (Phila) 2010; 3:140-7; PMID:20103729; DOI:10.1158/1940-6207.CAPR-09-0166.
49. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, et al. Aurora kinases A and B are upregulated by Myc and are essential for maintenance of the malignant state. Blood 2010; 116:1498-505; PMID:20519624; DOI:10.1182/blood-2009-11-251074.
50. Forshell LP, Li Y, Forshell TP, Rudelius M, Nilsson L, Keller U, et al. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget 2011; 2:448-60; PMID:21646687.
51. Bertoni F, Codegoni AM, Furlan D, Tibiletti MG, Capella C, Broggini M. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 1999; 26:176- 80; PMID:10469457; DOI:10.1002/(SICI)1098- 2264(199910)26:2〈176::AID-GCC11〉3.0.CO;2-3.
52. Menoyo A, Alazzouzi H, Espin E, Armengol M, Yamamoto H, Schwartz S Jr. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 2001; 61:7727-30; PMID:11691784.
53. Williams LH, Choong D, Johnson SA, Campbell IG. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon and ovarian cancers. Clin Cancer Res 2006; 12:6967-72; PMID:17145815; DOI:10.1158/1078-0432.CCR-06-1770.
54. Zhang P, Wang J, Gao W, Yuan BZ, Rogers J, Reed E. CHK2 kinase expression is downregulated due to promoter methylation in non-small cell lung cancer. Mol Cancer 2004; 3:14; PMID:15125777; DOI:10.1186/1476-4598-3-14.
55. Staalesen V, Falck J, Geisler S, Bartkova J, Borresen- Dale AL, Lukas J, et al. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 2004; 23:8535-44; PMID:15361853; DOI:10.1038/sj.onc.1207928.
56. Berge EO, Staalesen V, Straume AH, Lillehaug JR, Lonning PE. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. Biochim Biophys Acta 2010; 1803:386-95.
57. Golan A, Pick E, Tsvetkov L, Nadler Y, Kluger H, Stern DF. Centrosomal Chk2 in DNA damage responses and cell cycle progression. Cell Cycle 2010; 9:2647-56; PMID:20581449; DOI:10.4161/cc.9.13.12121.
58. Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 2007; 6:935-44; PMID:17363488; DOI:10.1158/1535-7163.MCT-06-0567.
59. Yu Q, Rose JH, Zhang H, Pommier Y. Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett 2001; 505:7-12; PMID:11557032; DOI:10.1016/S0014-5793(01)02756-9.
60. Zachos G, Black EJ, Walker M, Scott MT, Vagnarelli P, Earnshaw WC, et al. Chk1 is required for spindle checkpoint function. Dev Cell 2007; 12:247-60; PMID:17276342; DOI:10.1016/j.devcel.2007.01.003.
61. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. Chemopotentiation of temozolomide, irinotecan and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003; 2:371-82; PMID:12700281.
62. Höglund A, Nilsson L, Muralidharan SV, Hasvold LA, Merta P, Rudelius M, et al. Clin Cancer Res 2011; In press.